Literature DB >> 14688263

TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor.

Jun Xu1, Yun-Ju Lai, Weei-Chin Lin, Fang-Tsyr Lin.   

Abstract

Lysophosphatidic acid (LPA) induces actin rearrangement, focal adhesion assembly, and cell migration through the activation of small G protein Rho and its downstream effectors. These diverse cellular responses are mediated by its associated G protein-coupled receptors. However, the mechanisms and specificity by which these LPA receptors mediate LPA actions are still poorly understood. Here we show that LPA stimulation promotes the interaction of the LPA(2) receptor with a focal adhesion molecule, TRIP6 (thyroid receptor interacting protein 6)/ZRP-1 (zyxin-related protein 1). TRIP6 directly binds to the carboxyl-terminal tail of the LPA(2) receptor through its LIM domains. LPA-dependent recruitment of TRIP6 to the plasma membrane promotes its targeting to focal adhesions and co-localization with actin stress fibers. In addition, TRIP6 associates with the components of focal complexes including paxillin, focal adhesion kinase, c-Src, and p130(cas) in an agonist-dependent manner. Overexpression of TRIP6 augments LPA-induced cell migration; in contrast, suppression of endogenous TRIP6 expression by a TRIP6-specific small interfering RNA reduces it in SKOV3 ovarian cancer cells. Strikingly, the association with TRIP6 is specific to the LPA(2) receptor but not LPA(1) or LPA(3) receptor, indicating a specific role for TRIP6 in regulating LPA(2) receptor-mediated signaling. Taken together, our results suggest that TRIP6 functions at a point of convergence between the activated LPA(2) receptor and downstream signals involved in cell adhesion and migration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688263      PMCID: PMC3904432          DOI: 10.1074/jbc.M311891200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  34 in total

1.  Interplay between Rac and Rho in the control of substrate contact dynamics.

Authors:  K Rottner; A Hall; J V Small
Journal:  Curr Biol       Date:  1999-06-17       Impact factor: 10.834

Review 2.  The LIM domain: regulation by association.

Authors:  I Bach
Journal:  Mech Dev       Date:  2000-03-01       Impact factor: 1.882

3.  LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains.

Authors:  Y Wang; T D Gilmore
Journal:  Biochim Biophys Acta       Date:  2001-04-23

4.  Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.

Authors:  Y L Hu; M K Tee; E J Goetzl; N Auersperg; G B Mills; N Ferrara; R B Jaffe
Journal:  J Natl Cancer Inst       Date:  2001-05-16       Impact factor: 13.506

Review 5.  Lysophosphatidic acid receptors.

Authors:  J J Contos; I Ishii; J Chun
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

Review 6.  Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear.

Authors:  Yuan Wang; Thomas D Gilmore
Journal:  Biochim Biophys Acta       Date:  2003-02-17

7.  Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA.

Authors:  J J Contos; J Chun
Journal:  Genomics       Date:  2000-03-01       Impact factor: 5.736

8.  Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid.

Authors:  K Bandoh; J Aoki; H Hosono; S Kobayashi; T Kobayashi; K Murakami-Murofushi; M Tsujimoto; H Arai; K Inoue
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

9.  Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family.

Authors:  Kyoko Noguchi; Satoshi Ishii; Takao Shimizu
Journal:  J Biol Chem       Date:  2003-04-30       Impact factor: 5.157

10.  Zyxin and cCRP: two interactive LIM domain proteins associated with the cytoskeleton.

Authors:  I Sadler; A W Crawford; J W Michelsen; M C Beckerle
Journal:  J Cell Biol       Date:  1992-12       Impact factor: 10.539

View more
  43 in total

1.  Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.

Authors:  Xiaobing Miao; Xiaohong Xu; Yaxun Wu; Xinghua Zhu; Xudong Chen; Chunsun Li; Xiaoyun Lu; Yali Chen; Yushan Liu; Jieyu Huang; Yuchan Wang; Song He
Journal:  Tumour Biol       Date:  2015-08-23

2.  The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration.

Authors:  Yun-Ju Lai; Victor T G Lin; Ying Zheng; Etty N Benveniste; Fang-Tsyr Lin
Journal:  Mol Cell Biol       Date:  2010-09-27       Impact factor: 4.272

3.  c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation.

Authors:  Brooke K McMichael; Stephanie M Meyer; Beth S Lee
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

4.  Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect.

Authors:  Shuyu E; Yun-Ju Lai; Ryoko Tsukahara; Chen-Shan Chen; Yuko Fujiwara; Junming Yue; Jei-Hwa Yu; Huazhang Guo; Akio Kihara; Gábor Tigyi; Fang-Tsyr Lin
Journal:  J Biol Chem       Date:  2009-03-17       Impact factor: 5.157

5.  Zyxin is involved in thrombin signaling via interaction with PAR-1 receptor.

Authors:  Jingyan Han; Guoquan Liu; Jasmina Profirovic; Jiaxin Niu; Tatyana Voyno-Yasenetskaya
Journal:  FASEB J       Date:  2009-08-18       Impact factor: 5.191

6.  The lysophosphatidic acid type 2 receptor is required for protection against radiation-induced intestinal injury.

Authors:  Wenlin Deng; E Shuyu; Ryoko Tsukahara; William J Valentine; Gangadhar Durgam; Veeresa Gududuru; Louisa Balazs; Venkatraman Manickam; Marcello Arsura; Lester VanMiddlesworth; Leonard R Johnson; Abby L Parrill; Duane D Miller; Gabor Tigyi
Journal:  Gastroenterology       Date:  2007-03-24       Impact factor: 22.682

7.  Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.

Authors:  Gyöngyi N Kiss; James I Fells; Renuka Gupte; Sue-Chin Lee; Jianxiong Liu; Nóra Nusser; Keng G Lim; Ramesh M Ray; Fang-Tsyr Lin; Abby L Parrill; Balázs Sümegi; Duane D Miller; Gabor Tigyi
Journal:  Mol Pharmacol       Date:  2012-09-11       Impact factor: 4.436

8.  TRIP6 regulates p27 KIP1 to promote tumorigenesis.

Authors:  Victor T G Lin; Vivian Y Lin; Yun-Ju Lai; Chen-Shan Chen; Kang Liu; Weei-Chin Lin; Fang-Tsyr Lin
Journal:  Mol Cell Biol       Date:  2013-01-22       Impact factor: 4.272

9.  Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells.

Authors:  Yutaka Hasegawa; Mandi Murph; Shuangxing Yu; Gabor Tigyi; Gordon B Mills
Journal:  Mol Oncol       Date:  2008-06       Impact factor: 6.603

10.  Restriction to Fos family members of Trip6-dependent coactivation and glucocorticoid receptor-dependent trans-repression of activator protein-1.

Authors:  Markus Diefenbacher; Sylwia Sekula; Christine Heilbock; Jana V Maier; Margarethe Litfin; Hans van Dam; Marc Castellazzi; Peter Herrlich; Olivier Kassel
Journal:  Mol Endocrinol       Date:  2008-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.